Sutro Biopharma (STRO) Non Operating Income (2024 - 2026)

Sutro Biopharma (STRO) posted Non Operating Income of -$8.8 million for Q4 2025, down 4.73% sequentially from -$8.4 million in Q3 2025, and down 82.09% YoY from -$49.1 million in Q4 2024.

Sutro Biopharma (STRO) Non Operating Income (2024 - 2026) Analysis & Trends

Sutro Biopharma has reported Non Operating Income for 2 years, with the latest figure at -$8.8 million in Q4 2025.

  • Quarterly Non Operating Income fell 82.09% year-over-year to -$8.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$32.8 million (down 345.74% YoY) and the FY2025 annual result came in at -$32.8 million, down 345.69% from the prior year.
  • Non Operating Income eased to -$8.8 million in Q4 2025 per STRO's latest filing, from -$8.4 million in the prior quarter.
  • Over five years, Non Operating Income peaked at $19.1 million in Q3 2024 and troughed at -$8.8 million in Q4 2025.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Op. Inc. (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 234.30 Mn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - -139.24 Mn
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn -
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 12.40
7 Royalty Pharma 33.72 Bn 35.84 Bn - -51.63 Mn
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn -53.64 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn -
10 Sutro Biopharma 339.58 Mn 175.24 Mn - -8.64 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 -8.64 Mn
Dec 31, 2025 -8.80 Mn
Sep 30, 2025 -8.40 Mn
Jun 30, 2025 -8.17 Mn
Mar 31, 2025 -7.45 Mn
Dec 31, 2024 -4.83 Mn
Sep 30, 2024 19.13 Mn
Jun 30, 2024 675,000.00
Mar 31, 2024 -1.62 Mn